News & Events
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale (opens in a new tab)
CAMBRIDGE, Mass. , Jan. 16, 2025 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company’s previously announced sale of its VOWST business to…
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates (opens in a new tab)
New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo; data support the broader potential of Seres’ live…
GENETIC ANALYSIS AND FERRING PHARMACEUTICALS ANNOUNCE A COLLABORATION TO DEVELOP A NEW MICROBIOME RAPID DIAGNOSTIC TEST (opens in a new tab)
· Collaboration announced to develop and launch a new rapid microbiome-based PCR test, aiming to provide increased standardisation in a quickly evolving field of microbiome life science · Technology will allow researchers and clinicians to deploy Ferring’s Microbiome Health Index™ biomarker in a clinical setting, estab…
Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. , Dec. 16, 2024 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference . Eric Shaff , President and Chief Executive Officer, will…
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (opens in a new tab)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial bloodstream infections versus placebo Breakthrough Therapy meeting with FDA on next study of SER-155 in allo-HSCT expected in Q1 2025 Seres seeking SER-155…
Hello world! (opens in a new tab)
Welcome to WordPress. This is your first post. Edit or delete it, then start writing! The post Hello world! appeared first on Vedanta Biosciences, Inc .…
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. , Nov. 22, 2024 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff , President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36 th Annual Healthcare Conference…
Publication of Q3 Interim Report January – September 2024 (opens in a new tab)
The post Publication of Q3 Interim Report January – September 2024 appeared first on Genetic Analysis.…
Genetic Analysis AS: Interim report January – September 2024 (opens in a new tab)
OSLO, NORWAY – 15 November 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the third quarter and the first nine months of 2024. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the repo…
Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (opens in a new tab)
SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo, through day 100 post allo-HSCT Financial position…
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 (opens in a new tab)
CAMBRIDGE, Mass. , Nov. 06, 2024 (GLOBE NEWSWIRE) — Seres Therapeutics , Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 13, 2024 at 8:30 a.m.…
Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes (opens in a new tab)
VE303 high dose associated with reduction in antibiotic resistance genes (ARGs) High VE303 strain colonization also associated with reduced ARGs Presence of ARGs increases the risk of drug-resistant infections Pivotal Phase 3 trial, RESTORATiVE303, underway CAMBRIDGE, Mass., October 16, 2024 – Vedanta Biosciences, a la…
Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A (opens in a new tab)
Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections Cash received at completion, along with anticipated…
Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30 (opens in a new tab)
CAMBRIDGE, Mass. , Sept. 26, 2024 (GLOBE NEWSWIRE) — Seres Therapeutics , Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company’s VOWST business to…
Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. , Sept. 13, 2024 (GLOBE NEWSWIRE) — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that the Company, will participate in the Cantor Global Healthcare Conference and Eric Shaff , President and Chief Executive Officer, will represent…
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) (opens in a new tab)
SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo through day 100 post HSCT Demonstrated generally well tolerated safety…
Publication of Half-year report 2024 (opens in a new tab)
The post Publication of Half-year report 2024 appeared first on Genetic Analysis.…
Genetic Analysis AS: Publication of Half-year report 2024 (opens in a new tab)
OSLO, NORWAY – 30 August 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for H1, and april – June 2024. The Half-year report is available as an attached file to this release and on the Company’s website. Below is a summary of the report. Ronny Hermansen, CEO o…
Genetic Analysis AS launches the GA-map® Discovery reagent kit – a precision microbiome research assay (opens in a new tab)
The post Genetic Analysis AS launches the GA-map® Discovery reagent kit – a precision microbiome research assay appeared first on Genetic Analysis.…
Genetic Analysis directed issue to major shareholders has now been registered with the Norwegian Register of Business Enterprises (opens in a new tab)
Genetic Analysis AS’ (“GA” or the “Company”) directed issue to current major shareholders and certain members of the board of directors and management has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret). On July 1 and July 17, 2024, GA carried out the directed issue that…